Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.
In a double-blind randomised trial 129 patients with first myocardial infarction of less than 6 h duration were allocated to treatment with human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min, or to placebo infusion. Coronary angiography at the end of this infusion showed that the infarct-related vessel was patent in 61% of 62 assessable coronary angiograms in the rt-PA-treated group compared with 21% in the control group. Treatment with rt-PA was not accompanied by any major complications. In the rt-PA group the circulating fibrinogen level at the end of the catheterisation was 52 +/- 29% (mean +/- SD) of the starting value.
Verstraete
M
M
Bleifeld
W
W
Brower
R W
RW
Charbonnier
B
B
Collen
D
D
de Bono
D P
DP
Dunning
A J
AJ
Lennane
R J
RJ
Lubsen
J
J
Mathey
D G
DG
D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D011897:Random Allocation; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator